Inotiv, Inc. (NOTVQ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Inotiv, Inc. (NOTVQ) has a cash flow conversion efficiency ratio of -0.014x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.07 Million) by net assets ($77.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see NOTVQ market cap overview for the company's overall valuation and market capitalisation.
Inotiv, Inc. - Cash Flow Conversion Efficiency Trend (1997–2025)
This chart illustrates how Inotiv, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Inotiv, Inc. stock price today for real-time trading data and today's change.
Inotiv, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Inotiv, Inc. ranked by their cash flow conversion efficiency. Review how much free cash does Inotiv, Inc. generate to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Waverley Pharma Inc
V:WAVE
|
0.024x |
|
Recon Technology Ltd
NASDAQ:RCON
|
-0.015x |
|
Anexo Group Plc
LSE:ANX
|
-0.057x |
|
IMMERSION G. S.A. ZY 10
F:73W
|
3.367x |
|
GRIT Real Estate Income Group
LSE:GR1T
|
0.058x |
|
MEDCAW INVESTMENTS LS-01
F:U09
|
N/A |
|
ONETECH SOLUTIONS HOLDINGS BERHAD
KLSE:03041
|
-0.145x |
|
KlickOwn AG
STU:ILK1
|
N/A |
Annual Cash Flow Conversion Efficiency for Inotiv, Inc. (1997–2025)
The table below shows the annual cash flow conversion efficiency of Inotiv, Inc. from 1997 to 2025. Also see Inotiv, Inc. total assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $136.03 Million | $-10.46 Million | -0.077x | -92.58% |
| 2024-09-30 | $170.50 Million | $-6.80 Million | -0.040x | -138.43% |
| 2023-09-30 | $268.49 Million | $27.88 Million | 0.104x | +816.16% |
| 2022-09-30 | $359.77 Million | $-5.22 Million | -0.015x | -114.19% |
| 2021-09-30 | $105.13 Million | $10.75 Million | 0.102x | -39.81% |
| 2020-09-30 | $7.60 Million | $1.29 Million | 0.170x | +2.35% |
| 2019-09-30 | $10.71 Million | $1.78 Million | 0.166x | -48.21% |
| 2018-09-30 | $10.88 Million | $3.49 Million | 0.320x | +119.47% |
| 2017-09-30 | $8.47 Million | $1.24 Million | 0.146x | +2.71% |
| 2016-09-30 | $7.46 Million | $1.06 Million | 0.142x | -25.00% |
| 2015-09-30 | $10.72 Million | $2.03 Million | 0.189x | +7.31% |
| 2014-09-30 | $9.54 Million | $1.68 Million | 0.177x | +9.97% |
| 2013-09-30 | $9.46 Million | $1.52 Million | 0.161x | +870.02% |
| 2012-09-30 | $9.59 Million | $-200.00K | -0.021x | -129.88% |
| 2011-09-30 | $15.59 Million | $1.09 Million | 0.070x | -69.50% |
| 2010-09-30 | $10.67 Million | $2.44 Million | 0.229x | +16.05% |
| 2009-09-30 | $13.12 Million | $2.59 Million | 0.197x | +486.76% |
| 2008-09-30 | $17.80 Million | $598.00K | 0.034x | -78.71% |
| 2007-09-30 | $18.55 Million | $2.93 Million | 0.158x | -28.76% |
| 2006-09-30 | $17.35 Million | $3.84 Million | 0.222x | +902.04% |
| 2005-09-30 | $19.60 Million | $-541.25K | -0.028x | -118.93% |
| 2004-09-30 | $19.42 Million | $2.83 Million | 0.146x | -2.26% |
| 2003-09-30 | $19.73 Million | $2.95 Million | 0.149x | +38.82% |
| 2002-09-30 | $18.90 Million | $2.03 Million | 0.108x | -52.39% |
| 2001-09-30 | $17.83 Million | $4.03 Million | 0.226x | +772.94% |
| 2000-09-30 | $16.06 Million | $-539.16K | -0.034x | -136.51% |
| 1999-09-30 | $17.40 Million | $1.60 Million | 0.092x | -35.63% |
| 1998-09-30 | $16.80 Million | $2.40 Million | 0.143x | +23.21% |
| 1997-09-30 | $6.90 Million | $800.00K | 0.116x | -- |
About Inotiv, Inc.
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. The company operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences researc… Read more